|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer</span> risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups.
|
22729912 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The G allele of the TP53 R72P polymorphism and T allele of the MDM2 SNP309 polymorphism were putative high-risk alleles and exhibited a combined gene-dose-dependent joint effect on breast cancer risk that was more clearly observed in postmenopausal women.
|
21833626 |
2011 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
|
21706156 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.
|
19639206 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analyses indicate that MDM2 SNP309 serves as a tumor susceptibility marker, and that there is an association between MDM2 SNP309 and p53 Arg72Pro regarding tumor susceptibility.
|
21619694 |
2011 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we investigated whether MDM2-SNP309 is associated with p53 R72P genetic polymorphism for the risk of breast cancer development in Asian Taiwanese, which has not been well-studied in this regard.
|
21479369 |
2011 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no evidence of such an effect on survival within the TP53-mutated tumor group for TP53 R72P carriers but a suggestion of an effect for MDM2 SNP309 carriers (GG vs. TT-genotype HR 2.99, P = 0.06).
|
21667122 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNP) in codon Arg72Pro of P53 results in impairment of the tumor suppressor activity of the gene.
|
23167335 |
2012 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we investigated whether MDM2-SNP309 is associated with p53 R72P genetic polymorphism for the risk of breast cancer development in Asian Taiwanese, which has not been well-studied in this regard.
|
21479369 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined.
|
19451596 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
|
16258005 |
2006 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749).
|
20021639 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
|
21706156 |
2012 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymorphisms were identified within the TP53 (R72P and Ins16) and MDM2 (SNP309) genes that may further diminish TP53 tumor suppressor activity.
|
19046423 |
2008 |